Please assess the completion status of the following clinical trial:

Trial Title: A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed or suspected metastatic ccRCC~2. Age ≥ 18 y~3. Written informed consent provided for participation in the trial~4. In the opinion of investigator, willing and able to comply with required study procedures.~Exclusion Criteria:~1. Patients on VEGF TKI treatment \< 1 week before 68Ga-NY104 PET/CT. TKI is known to affect girentuximab binding in patients with ccRCC. If patients were on VEGF TKI treatment, such as sunitinib, sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68Ga-NY104 PET/CT is required.~2. Pregnancy or breastfeeding.~3. Severe claustrophobia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET scan (Type: EXPERIMENTAL): Patients will receive an intravenous injection of 68Ga-NY104

Based on this trial design, predict the completion outcome and termination type (if applicable).